拨康视云“四闯”港交所背后:四年累亏3.3亿美元,股东“内耗”、产品商业化困局待解

华夏时报
22 Jun

本报(chinatimes.net.cn)记者郭怡琳 于娜 北京报道改良阿托品背后公司第四次递交招股书,拟在香港主板上市。近日,临床阶段眼科生物科技公司Cloudbreak Pharma Inc.(下称“拨康视云”)再次于港交所递交招股书,联席保荐人为建银国际及华泰国际。此前,该公司曾于2023年11月、2024年5月、2024年12月2日向港交所提交过上市申请书,但最终均以“失效”告终。招股书...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10